In this meta-analysis, we provided evidence that, in patients with advanced NSCLC, the variant XRCC3 241Met allele could predict good response to platinum-based chemotherapy, especially in Caucasian population; while there was no significant association of XRCC3 Thr241Met polymorphism with survival. This evidence concerns the gene XRCC3 and non-small cell lung carcinoma.